Past as Prologue-Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination.

COVID-19 Rubella vaccination SARS-CoV-2 coronavirus disease respiratory infections severe acute respiratory syndrome coronavirus 2 vaccine-preventable diseases viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 15 12 2022
Statut: ppublish

Résumé

The rapid rollout of vaccines against COVID-19 as a key mitigation strategy to end the global pandemic might be informed by lessons learned from rubella vaccine implementation in response to the global rubella epidemic of 1963-1965. That rubella epidemic led to the development of a rubella vaccine that has been introduced in all but 21 countries worldwide and has led to elimination of rubella in 93 countries. Although widespread introduction and use of rubella vaccines was slower than that for COVID-19 vaccines, the process can provide valuable insights for the continued battle against COVID-19. Experiences from the rubella disease control program highlight the critical and evolving elements of a vaccination program, including clearly delineated goals and strategies, regular data-driven revisions to the program based on disease and vaccine safety surveillance, and evaluations to identify the vaccine most capable of achieving disease control targets.

Identifiants

pubmed: 36502405
doi: 10.3201/eid2813.220604
pmc: PMC9745252
doi:

Substances chimiques

COVID-19 Vaccines 0
Rubella Vaccine 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S225-S231

Références

Vaccine. 2021 Feb 5;39(6):889-900
pubmed: 33454135
N Engl J Med. 2022 Mar 24;386(12):1176-1179
pubmed: 35196425
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
MMWR Morb Mortal Wkly Rep. 2005 Mar 25;54(11):279-82
pubmed: 15788995
MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-1645
pubmed: 34818318
Epidemiol Rev. 2002;24(2):125-36
pubmed: 12762088
J Travel Med. 2022 May 31;29(3):
pubmed: 35262737
JAMA Pediatr. 2014 Feb;168(2):148-55
pubmed: 24311021
JAMA Pediatr. 2017 Aug 1;171(8):719-720
pubmed: 28654956
CDR (Lond Engl Rev). 1991 Mar 29;1(4):R33-7
pubmed: 1669769
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520-1524
pubmed: 34710075
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176
pubmed: 34437525
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):196-201
pubmed: 35143468
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
J Infect Dis. 2011 Sep 1;204 Suppl 2:S713-7
pubmed: 21954271
Wkly Epidemiol Rec. 2011 Jul 15;86(29):301-16
pubmed: 21766537
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):
pubmed: 34376550
J Infect Public Health. 2021 Oct;14(10):1299-1312
pubmed: 34429257
Epidemiol Infect. 1991 Aug;107(1):17-30
pubmed: 1879482
Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S123-5
pubmed: 16998770
BMJ. 1999 Mar 20;318(7186):769-70
pubmed: 10082699
J Travel Med. 2021 Oct 11;28(7):
pubmed: 34369565
Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S164-8
pubmed: 16998777
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
JAMA. 1973 Aug 6;225(6):585-90
pubmed: 4740523

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH